Arvaya Healthcare Secures BSE In-Principle Approval for Preferential Equity Issue
Bijoy Hans Ltd 路 Others (Uncategorized) 路 13 Oct 2026, 12:12 am
Arvaya Healthcare Secures BSE In-Principle Approval for Preferential Equity Issue Arvaya Healthcare Limited received in-principle approval from BSE on 12th Oct'26 for the preferential issuance of 3,871,854 equity shares at an issue price of Rs. 40 per share (face value Rs. 10 each). The allotment is designated for non-promoters pursuant to a share swap arrangement. The approval is subject to statutory compliances under SEBI ICDR and LODR Regulations, including mandatory lock-in guidelines and submission of a listing application within 20 days post-allotment.
Original exchange filing (PDF)
More announcements from Bijoy Hans Ltd
- The investor call arranged by the company on 16th November,2026 was concluded successfully. Please find attached herewith Audio for the same. 路 17 Nov 2026
- Investor Presentation in relation with the Unaudited Standalone and consolidated Financial Results of the Company for the quarter and half year ended on September 30 2026 and overall company .... 路 16 Nov 2026
- Unaudited Standalone and Consolidated financial results for the quarter ended 30th September 2026 路 14 Nov 2026
- Statement of Deviation and Variation for the quarter ended 30th September 2026 is not applicable to the Company. 路 14 Nov 2026
- Declaration of Unaudited standalone and consolidated Financial Results for the half year ended and 2nd quarter ended 30th September 2026 路 14 Nov 2026
- Revision in intimation and In compliance with the provisions of Regulation 30 of SEBI (LODR) Regulations 2015, we would like to inform you that Arvaya Healthcare Limited (formerly known .... 路 16 Nov 2026
- In compliance with the provisions of Regulation 30 of SEBI (LODR) Regulations 2015, we would like to inform you that Arvaya Healthcare Limited (formerly known as Bijoy Hans Limited) (''the .... 路 16 Nov 2026
- Arvaya Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Pursuant to the provisions .... 路 13 Nov 2026
